These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 15718328)
21. Endostatin: the logic of antiangiogenic therapy. Abdollahi A; Hlatky L; Huber PE Drug Resist Updat; 2005; 8(1-2):59-74. PubMed ID: 15939343 [TBL] [Abstract][Full Text] [Related]
22. The potential of antiangiogenic therapy in non-small cell lung cancer. Giaccone G Clin Cancer Res; 2007 Apr; 13(7):1961-70. PubMed ID: 17404076 [TBL] [Abstract][Full Text] [Related]
23. Novel targets and approaches in advanced prostate cancer. Hadaschik BA; Sowery RD; Gleave ME Curr Opin Urol; 2007 May; 17(3):182-7. PubMed ID: 17414516 [TBL] [Abstract][Full Text] [Related]
24. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors. Idbaih A; Ducray F; Sierra Del Rio M; Hoang-Xuan K; Delattre JY Oncologist; 2008 Sep; 13(9):978-92. PubMed ID: 18779539 [TBL] [Abstract][Full Text] [Related]
25. Targeting angiogenesis in head and neck cancer. Seiwert TY; Cohen EE Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442 [TBL] [Abstract][Full Text] [Related]
26. Targeting angiogenesis with integrative cancer therapies. Yance DR; Sagar SM Integr Cancer Ther; 2006 Mar; 5(1):9-29. PubMed ID: 16484711 [TBL] [Abstract][Full Text] [Related]
27. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. Lee L; Sharma S; Morgan B; Allegrini P; Schnell C; Brueggen J; Cozens R; Horsfield M; Guenther C; Steward WP; Drevs J; Lebwohl D; Wood J; McSheehy PM Cancer Chemother Pharmacol; 2006 Jun; 57(6):761-71. PubMed ID: 16172907 [TBL] [Abstract][Full Text] [Related]
28. Current development status of small-molecule vascular disrupting agents. Chaplin DJ; Horsman MR; Siemann DW Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022 [TBL] [Abstract][Full Text] [Related]
29. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673 [TBL] [Abstract][Full Text] [Related]
31. Advanced renal cell carcinoma: what to do after first line antiangiogenic therapy? Soulières D Curr Opin Support Palliat Care; 2009 Sep; 3(3):153-6. PubMed ID: 19512932 [TBL] [Abstract][Full Text] [Related]
32. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Tortora G; Ciardiello F; Gasparini G Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498 [TBL] [Abstract][Full Text] [Related]